<DOC>
	<DOCNO>NCT00117910</DOCNO>
	<brief_summary>This open-label , multicenter study explore primary secondary prophylaxis treatment single , fixed-dose , subcutaneous ( SC ) injection pegfilgrastim elderly subject high-risk breast cancer receive myelosuppressive chemotherapy . The primary objective provide preliminary information incidence protocol define neutropenic event chemotherapy cycle 1 .</brief_summary>
	<brief_title>Treatment Elderly Patients With High Risk Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Highrisk , stage IIIII breast cancer suitable treatment 6 cycle FEC100 Chemotherapy Histologically proven great equal 1 axillary node positive Oestrogen receptor negative positive Chemotherapy naïve VES 13 ( Vulnerable Elders Survey ) score less equal 3 ECOG performance status less equal 2 ANC great equal 1.5 x 10^9/L Platelets great equal 100 x 10^9/L Adequate renal function ( serum creatinine le 1.5 x upper limit normal ( ULN ) ) Before study specific procedure subject must give write informed consent participation study Total serum bilirubin great ULN accord institutional standard Clinically significant cardiac disease would preclude use epirubicin ( e.g. , LVEF ( leave ventricular ejection fraction ) ) less 45 % rest MUGA echocardiogram Prior bone marrow stem cell transplantation Any premalignant myeloid condition malignancy myeloid characteristic ( e.g. , myelodysplastic syndrome , acute chronic myelogenous leukaemia ) History prior malignancy breast cancer exception curatively treat basal cell carcinoma , situ cervical carcinoma surgically cured malignancy Prior radiation therapy Active infection administration systemic antibiotic antiinfectives within 72 hour start chemotherapy Known hypersensitivity E coliderived product ( e.g. , Filgrastim , HUMULIN® , Insulin , LAsparaginase , HUMATROPE® , Growth Hormone , INTRON A® ) Previous exposure pegfilgrastim previous entry study Known HIV infection Inability understand nature study provide write informed consent Subject currently enrol another investigational device drug trial ( ) receive investigational agent ( ) , exception placebotreated subject , within last 30 day Concerns subject 's compliance protocol procedure</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Aged , Granulocyte Colony-Stimulating Factor</keyword>
	<keyword>Combined Modality Therapy , Neutropenia</keyword>
	<keyword>pegfilgrastim , Neulasta®</keyword>
	<keyword>FEC-100 , Antineoplastic Agents</keyword>
	<keyword>Breast Cancer , Female</keyword>
</DOC>